玻璃体内注射阿非利塞联合与不加气压置换治疗伴息肉样脉络膜血管病变的黄斑下出血。

IF 0.5 Q4 OPHTHALMOLOGY
Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida
{"title":"玻璃体内注射阿非利塞联合与不加气压置换治疗伴息肉样脉络膜血管病变的黄斑下出血。","authors":"Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida","doi":"10.1177/24741264251335629","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To compare the visual outcomes of intravitreal (IVT) aflibercept with pneumatic displacement vs without pneumatic displacement for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). <b>Methods:</b> This retrospective study assessed patients with SMH associated with PCV who were treated with aflibercept and pneumatic displacement with gas (aflibercept+gas group) or with aflibercept alone (monotherapy group). Patients were followed for at least 12 months, with the best-corrected visual acuity (BCVA) at 12 months the primary outcome measure. <b>Results:</b> Forty-seven eyes of 47 patients were retrospectively analyzed from August 2013 to March 2023. The aflibercept+gas group comprised 25 eyes and the monotherapy group, 22 eyes. The 2 groups had comparable baseline characteristics. The mean logMAR best-corrected visual acuity (BCVA) before treatment was 0.78 ± 0.46 in the aflibercept+gas group and 0.83 ± 0.66 in the monotherapy group (<i>P</i> = .76). The mean BCVA (0.26 ± 0.42 vs 0.85 ± 0.57) and the mean change in (-0.52 ± 0.55 vs 0.02 ± 0.75) 12 months postoperatively was significantly better in the aflibercept+gas group than in the monotherapy group (<i>P</i> < .001 and <i>P</i> < .008, respectively). The BCVA improved by 3 or more lines in 60.0% of eyes in the aflibercept+gas group but in only 18.2% of eyes in the monotherapy group. Vitreous hemorrhage developed in 16.0% of eyes in the aflibercept+gas group and in 13.6% of eyes in the monotherapy group and retinal detachment in 4.0% and 0%, respectively (both <i>P</i> = 1.000). <b>Conclusions:</b> Better visual outcomes were achieved with IVT aflibercept and pneumatic displacement than with aflibercept alone for SMH associated with PCV.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251335629"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031733/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy.\",\"authors\":\"Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida\",\"doi\":\"10.1177/24741264251335629\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> To compare the visual outcomes of intravitreal (IVT) aflibercept with pneumatic displacement vs without pneumatic displacement for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). <b>Methods:</b> This retrospective study assessed patients with SMH associated with PCV who were treated with aflibercept and pneumatic displacement with gas (aflibercept+gas group) or with aflibercept alone (monotherapy group). Patients were followed for at least 12 months, with the best-corrected visual acuity (BCVA) at 12 months the primary outcome measure. <b>Results:</b> Forty-seven eyes of 47 patients were retrospectively analyzed from August 2013 to March 2023. The aflibercept+gas group comprised 25 eyes and the monotherapy group, 22 eyes. The 2 groups had comparable baseline characteristics. The mean logMAR best-corrected visual acuity (BCVA) before treatment was 0.78 ± 0.46 in the aflibercept+gas group and 0.83 ± 0.66 in the monotherapy group (<i>P</i> = .76). The mean BCVA (0.26 ± 0.42 vs 0.85 ± 0.57) and the mean change in (-0.52 ± 0.55 vs 0.02 ± 0.75) 12 months postoperatively was significantly better in the aflibercept+gas group than in the monotherapy group (<i>P</i> < .001 and <i>P</i> < .008, respectively). The BCVA improved by 3 or more lines in 60.0% of eyes in the aflibercept+gas group but in only 18.2% of eyes in the monotherapy group. Vitreous hemorrhage developed in 16.0% of eyes in the aflibercept+gas group and in 13.6% of eyes in the monotherapy group and retinal detachment in 4.0% and 0%, respectively (both <i>P</i> = 1.000). <b>Conclusions:</b> Better visual outcomes were achieved with IVT aflibercept and pneumatic displacement than with aflibercept alone for SMH associated with PCV.</p>\",\"PeriodicalId\":17919,\"journal\":{\"name\":\"Journal of VitreoRetinal Diseases\",\"volume\":\" \",\"pages\":\"24741264251335629\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031733/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of VitreoRetinal Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/24741264251335629\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264251335629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:比较加压置换与不加压置换玻璃体内注射阿布西贝治疗黄斑下出血(SMH)合并息肉样脉络膜血管病变(PCV)的视觉效果。方法:本回顾性研究评估了阿非利西普联合气体充气置换(阿非利西普+气体组)或单独阿非利西普(单药治疗组)治疗的SMH合并PCV患者。患者随访至少12个月,以12个月时的最佳矫正视力(BCVA)为主要指标。结果:回顾性分析2013年8月至2023年3月47例患者的47只眼。afliberept +gas组25只眼,单药组22只眼。两组具有可比较的基线特征。阿非利西普+气体组治疗前平均logMAR最佳矫正视力(BCVA)为0.78±0.46,单药组为0.83±0.66 (P = 0.76)。术后12个月的平均BCVA(0.26±0.42 vs 0.85±0.57)和平均变化(-0.52±0.55 vs 0.02±0.75)明显优于单药组(P < 0.001和P < 0.008)。afliberept +gas组60.0%的眼睛BCVA改善了3条或更多线,而单药组只有18.2%的眼睛BCVA改善。afliberept +gas组和单药组分别有16.0%和13.6%的眼出现玻璃体出血,分别有4.0%和0%的眼出现视网膜脱离(P均= 1.000)。结论:与单独使用阿非利西普治疗SMH合并PCV相比,静脉注射阿非利西普联合气动置换治疗的视力效果更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy.

Purpose: To compare the visual outcomes of intravitreal (IVT) aflibercept with pneumatic displacement vs without pneumatic displacement for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study assessed patients with SMH associated with PCV who were treated with aflibercept and pneumatic displacement with gas (aflibercept+gas group) or with aflibercept alone (monotherapy group). Patients were followed for at least 12 months, with the best-corrected visual acuity (BCVA) at 12 months the primary outcome measure. Results: Forty-seven eyes of 47 patients were retrospectively analyzed from August 2013 to March 2023. The aflibercept+gas group comprised 25 eyes and the monotherapy group, 22 eyes. The 2 groups had comparable baseline characteristics. The mean logMAR best-corrected visual acuity (BCVA) before treatment was 0.78 ± 0.46 in the aflibercept+gas group and 0.83 ± 0.66 in the monotherapy group (P = .76). The mean BCVA (0.26 ± 0.42 vs 0.85 ± 0.57) and the mean change in (-0.52 ± 0.55 vs 0.02 ± 0.75) 12 months postoperatively was significantly better in the aflibercept+gas group than in the monotherapy group (P < .001 and P < .008, respectively). The BCVA improved by 3 or more lines in 60.0% of eyes in the aflibercept+gas group but in only 18.2% of eyes in the monotherapy group. Vitreous hemorrhage developed in 16.0% of eyes in the aflibercept+gas group and in 13.6% of eyes in the monotherapy group and retinal detachment in 4.0% and 0%, respectively (both P = 1.000). Conclusions: Better visual outcomes were achieved with IVT aflibercept and pneumatic displacement than with aflibercept alone for SMH associated with PCV.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
16.70%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信